Arexvy: Canada approves GSK’s RSV vaccine
- 05-Nov-2024
GSK has received Canadian approval for Arexvy, its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country’s first authorized RSV shot for that age group. The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in […]
Pfizer RSV vaccine 82% effective vs severe infection
- 06-Apr-2023
Pfizer’s experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study. Final data from the study that was halted early when it became clear […]